Table 2 Comparison of patients with or without follow-up
|  | With follow-up (n = 846) | Without follow-up (n = 321) |
|---|---|---|
Age, mean years ± SD | 64.2 ± 11.1 | 73.7 ± 10.9* |
Male gender (%) | 58.2 | 56.2 |
Body Mass Index (mean kg/m2 ± SD) | 27.1 ±4.1 | 27.9 ±5.1 |
Diabetes (%) | 68.1 | 65.9 |
Hypertension (%) | 78.1 | 77.7 |
Hyperlipidemia (%) | 79.5 | 79.8 |
Smoking | ||
Current (%) | 19.3 | 20.1 |
Previous (%) | 36.5 | 36.8 |
mean packs*years ± SD | 31.8 ±26.5 | 32.9 ±28.5 |
Waist circumference (%) | ||
men (% ≥ 102 cm) | 48.1 | 47.1 |
women (% ≥ 88 cm) | 79.4 | 78.2 |
Blood pressure | ||
systolic (mean mmHg ± SD) | 135 ±14.2 | 133 ±15.2 |
diastolic (mean mmHg ± SD) | 78 ±11.4 | 77 ±11.3 |
Laboratory parameters (%) | ||
Total cholesterol (mg/dl) | 181 ± 46.3 | 183 ± 47.1 |
HDL-cholesterol (mg/dl) | 46 ± 15.2 | 48 ± 14.2 |
LDL-cholesterol (mg/dl) | 108 ± 39.8 | 106 ± 37.8 |
Triglycerides (mg/dl) | 142 ± 70.4 | 141 ± 70.8 |
Pharmacotherapy | ||
Lipid lowering agents (%) | 63.1 | 63.9 |
ARB/ACEi (%) | 45.6 | 43.6 |
Betablocker (%) | 44.7 | 46.7 |
Calciumantagonists (%) | 26.5 | 25.9 |
Insulin | 5.4 | 5.7 |
Oral antidiabetic drugs | 14.3 | 14.2 |
Functional assessment | ||
NIH Stroke Scale (median, range) | 3.0 (0–25) | 3.0 (0–25) |
Barthel Index (median, range) | 86 (0–100) | 87 (0–100) |
Origin of Stroke (TOAST) | ||
Large artery atherosclerosis | 40.9 | 40.8 |
Cardioembolic | 22.1 | 21.9 |
Small vessel disease | 18.5 | 18.8 |
Other aetiology | 4.6 | 4.5 |
Undetermined aetiology | 13.9 | 14.0 |